How I treat acquired aplastic anemia
- PMID: 28096088
- DOI: 10.1182/blood-2016-08-693481
How I treat acquired aplastic anemia
Abstract
Acquired severe aplastic anemia (SAA) is a rare hematologic disease associated with significant morbidity and mortality. Immune destruction of hemopoietic stem cells plays an important role in pathogenesis, as shown by successful treatment with immunosuppressive agents, leading to transfusion independence or complete recovery of peripheral blood counts in a proportion of patients. Growth factors can be combined with immunosuppressive therapy (IST) and may improve response rates, as recently shown with thrombopoietin analogs. Anabolic steroids may still play a role in combination with IST. The problem with IST is failure to respond and the development of late clonal disorders. Bone marrow transplantation (BMT) is the other therapeutic option: a matched sibling donor remains the best choice. For patients lacking a matched family donor, unrelated donors can be readily found, although mostly for patients of Caucasian origin. Other BMT options include unrelated cord blood or mismatched family donors. Acute and chronic graft-versus-host disease remain important complications of BMT. Patient age is a strong predictor of outcome for both IST and BMT, and must be considered when designing therapeutic strategies. Early diagnosis and treatment, as well as long-term monitoring, remain crucial steps for successful treatment of SAA.
© 2017 by The American Society of Hematology.
Similar articles
-
A study assessing the feasibility of randomization of pediatric and young adult patients between matched unrelated donor bone marrow transplantation and immune-suppressive therapy for newly diagnosed severe aplastic anemia: A joint pilot trial of the North American Pediatric Aplastic Anemia Consortium and the Pediatric Transplantation and Cellular Therapy Consortium.Pediatr Blood Cancer. 2020 Oct;67(10):e28444. doi: 10.1002/pbc.28444. Epub 2020 Aug 9. Pediatr Blood Cancer. 2020. PMID: 32776425 Free PMC article. Clinical Trial.
-
Bone marrow transplantation versus immunosuppressive therapy in patients with acquired severe aplastic anemia.Int J Hematol. 2016 Aug;104(2):168-74. doi: 10.1007/s12185-016-2037-8. Epub 2016 Jun 8. Int J Hematol. 2016. PMID: 27278666 Review.
-
Comparison of long-term outcome of children with severe aplastic anemia treated with immunosuppression versus bone marrow transplantation.Biol Blood Marrow Transplant. 1997 Apr;3(1):18-24. Biol Blood Marrow Transplant. 1997. PMID: 9209737
-
Similar outcome of upfront-unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK Paediatric BMT Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of EBMT.Br J Haematol. 2015 Nov;171(4):585-94. doi: 10.1111/bjh.13614. Epub 2015 Jul 28. Br J Haematol. 2015. PMID: 26223288
-
Aplastic anemia: therapeutic updates in immunosuppression and transplantation.Hematology Am Soc Hematol Educ Program. 2012;2012:292-300. doi: 10.1182/asheducation-2012.1.292. Hematology Am Soc Hematol Educ Program. 2012. PMID: 23233595 Review.
Cited by
-
Successful management with urgent haploidentical-peripheral blood stem cell transplantation for a patient with severe aplastic anaemia who developed disseminated fungal infection following immunosuppressive therapy.EJHaem. 2024 Jul 17;5(5):1072-1075. doi: 10.1002/jha2.917. eCollection 2024 Oct. EJHaem. 2024. PMID: 39415920 Free PMC article.
-
Hematopoietic stem cell transplantation activity in China 2022-2023. The proportions of peripheral blood for stem cell source continue to grow: a report from the Chinese Blood and Marrow Transplantation Registry Group.Bone Marrow Transplant. 2024 Sep 25. doi: 10.1038/s41409-024-02419-8. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 39322652
-
Long-term survival after unrelated donor marrow transplantation for aplastic anaemia after optimized conditioning regimen: a retrospective multicentre cohort study.EClinicalMedicine. 2024 Sep 5;76:102819. doi: 10.1016/j.eclinm.2024.102819. eCollection 2024 Oct. EClinicalMedicine. 2024. PMID: 39290639 Free PMC article.
-
Porcine Anti-Lymphocyte Globulin, Cyclosporine A Plus Thrombopoietin Receptor Agonists Achieved Similar Efficacy and Survival Compared to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Aplastic Anemia.Int J Gen Med. 2024 Sep 13;17:4025-4036. doi: 10.2147/IJGM.S465184. eCollection 2024. Int J Gen Med. 2024. PMID: 39290233 Free PMC article.
-
Long-Term Outcome of Eltrombopag With First-Line Immunosuppressive Therapy for Newly Diagnosed Severe Aplastic Anemia.J Hematol. 2024 Aug;13(4):142-149. doi: 10.14740/jh1289. Epub 2024 Aug 10. J Hematol. 2024. PMID: 39247063 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical